dc.contributorMolano, Julian
dc.contributorCarvajal, Luis Leonardo
dc.creatorOrdoñez Sanchez, Salvador
dc.creatorHernandez, Gilmar
dc.date.accessioned2019-02-12T14:38:53Z
dc.date.available2019-02-12T14:38:53Z
dc.date.created2019-02-12T14:38:53Z
dc.date.issued2019
dc.identifierhttp://repository.urosario.edu.co/handle/10336/19043
dc.identifierhttps://doi.org/10.48713/10336_19043
dc.description.abstractINTRODUCTION: The objective of this work is to describe the clinical characteristics, the isolated germs in cultures taken in surgery, the type of surgical procedures and the outcomes in the treatment performed in patients with diabetic foot in the Hospital Universitario Mayor – Mederi. MATERIALS AND METHODS: Retrospective observational descriptive study in a serial clinical cases of the results obtained from the culture samples taken intra-surgically, the clinical characteristics of the patients, the number and type of procedures performed by the Orthopedic Service at the Hospital Universitario Mayor – Universidad del Rosario between January 2012 and December 2016 due to complications derived from diabetic foot. RESULTS: We obtained 58 patients with an average age of 65 years, 69% men and 31% women. The intraoperative Wagner stage was 32.8% III, 50% IV. Germs isolated, in the first place were found 2 types of germs, each in 15.5% of the cultures, which are Escherichia Coli and Pseudomonas Aeruginosa. One third of the patients required major amputations, of which 46.6% had infections due to multi-resistant germs such as multiresistant Escherichia coli, 93.3% of them required change in the empirical antibiotic therapy. CONCLUSIONS: The predominant germs are gram-negative bacilli like multi-resistant enterobacteria and Pseudomonas aeruginosa. Due that there was a 77.5% change in antibiotic therapy, we suggest taking samples intra-surgically for microbiological isolation prior to empirical antibiotic therapy and due the isolated bacterial flora in this series we suggest the use of carbapenems as empirical antibiotic therapy in the Hospital Universitario Mayor.
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherEspecialización en Ortopedia y Traumatología HOK
dc.publisherFacultad de Medicina
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.sourceAbdulrazak A, Ibrahim Bitar Z, Ayesh Al-Shamali A, Ahmed Mobasher L. Bacteriological study of diabetic foot infections. J Diabetes Complications. 2005;19(3):138-141. doi:10.1016/j.jdiacomp.2004.06.001
dc.sourcePittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD. Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up. Arch Intern Med. 1999;159(8):851-856. http://www.ncbi.nlm.nih.gov/pubmed/10219931. Accessed February 5, 2019.
dc.sourceErtugrul MB, Baktiroglu S, Salman S, et al. Pathogens isolated from deep soft tissue and bone in patients with diabetic foot infections. J Am Podiatr Med Assoc. 98(4):290-295. http://www.ncbi.nlm.nih.gov/pubmed/18685049. Accessed February 5, 2019
dc.sourceMitchell SL, Shaffer ML, Loeb MB, et al. Infection Management and Multidrug-Resistant Organisms in Nursing Home Residents With Advanced Dementia. JAMA Intern Med. 2014;174(10):1660. doi:10.1001/jamainternmed.2014.3918
dc.sourceJúbiz Yamile, Márquez S Gustavo, Márquez Z Alvaro BJ. COLPEDIS, Grupo Colombiano de Pie Diabético. Guías colombianas para la prevención, diagnóstico y tratamiento del pie diabético 2012. 2012.
dc.sourceLima A, Godoy-Santos A, Sosa Anibal CP, et al. Directrices Panamericanas Para El Tratamiento de Infecciones En Úlceras Neuropáticas de Las Extremidades Inferiores. Vol 13,1 Supl.; 2011
dc.sourceMendes JJ, Marques-Costa A, Vilela C, et al. Clinical and bacteriological survey of diabetic foot infections in Lisbon. Diabetes Res Clin Pract. 2012;95(1):153-161. doi:10.1016/j.diabres.2011.10.001
dc.sourceCunha BA. Antibiotic selection for diabetic foot infections: a review. J Foot Ankle Surg. 39(4):253-257. http://www.ncbi.nlm.nih.gov/pubmed/10949806. Accessed February 5, 2019.
dc.sourceBridges RM, Deitch EA. Diabetic foot infections. Pathophysiology and treatment. Surg Clin North Am. 1994;74(3):537-555. http://www.ncbi.nlm.nih.gov/pubmed/8197529. Accessed February 5, 2019
dc.sourceComunicaciones G De, Restrepo AL. Colombia Ministerio de Salud y Protección Social. Plan Decenal de Salud Pública, PDSP, 2012-2021. 2013;(32):2012-2021. doi:10.1007/BF01050800
dc.sourcePathare NA, Bal A, Talvalkar G V, Antani DU. Diabetic foot infections: a study of microorganisms associated with the different Wagner grades. Indian J Pathol Microbiol. 1998;41(4):437-441. http://www.ncbi.nlm.nih.gov/pubmed/9866905. Accessed February 6, 2019.
dc.sourcePittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD. Outcome of diabetic foot infections treated conservatively: a retrospective 34 cohort study with long-term follow-up. Arch Intern Med. 1999;159(8):851-856. http://www.ncbi.nlm.nih.gov/pubmed/10219931. Accessed February 6, 2019
dc.sourceTiwari S, Pratyush DD, Dwivedi A, Gupta SK, Rai M, Singh SK. Microbiological and clinical characteristics of diabetic foot infections in northern India. J Infect Dev Ctries. 2012;6(4):329-332. http://www.ncbi.nlm.nih.gov/pubmed/22505442. Accessed February 6, 2019.
dc.sourceShankar EM, Mohan V, Premalatha G, Srinivasan RS, Usha AR. Bacterial etiology of diabetic foot infections in South India. Eur J Intern Med. 2005;16(8):567-570. doi:10.1016/j.ejim.2005.06.016
dc.sourceRaja NS. Microbiology of diabetic foot infections in a teaching hospital in Malaysia: a retrospective study of 194 cases. J Microbiol Immunol Infect. 2007;40(1):39-44. http://www.ncbi.nlm.nih.gov/pubmed/17332905. Accessed February 6, 2019
dc.sourceLipsky. A Current Approach to Diabetic Foot Infections. Curr Infect Dis Rep. 1999;1(3):253-260. http://www.ncbi.nlm.nih.gov/pubmed/11095796. Accessed February 6, 2019.
dc.sourceBiomerieux. http://www.biomerieux.com/en/identification-and-antibioticsusceptibility- testing.
dc.sourceCLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Eleventh Edition. CLSI Document M02-A11. Wayne, PA: Clinical and Laboratory Standards Institute; Vol 32.; 2012. doi:M02-A11
dc.sourceMartínez-Gómez DDA, Ramírez-Almagro C, Campillo-Soto Á, Morales- Cuenca G, Pagán-Ortiz J, Aguayo-Albasini JL. Infecciones del pie diabético. Prevalencia de los distintos microorganismos y sensibilidad a los antimicrobianos. Enferm Infecc Microbiol Clin. 2009;27(6):317-321. doi:10.1016/j.eimc.2008.07.004
dc.sourceLipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev. 2004;20(SUPPL. 1):68-77. doi:10.1002/dmrr.453
dc.sourceGraffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother. 2002;49(6):999- 1005. http://www.ncbi.nlm.nih.gov/pubmed/12039892. Accessed January 14, 2019.
dc.sourceBoulton AJM, Kirsner RS, Vileikyte L. Neuropathic Diabetic Foot Ulcers. N Engl J Med. 2004;351(1):48-55. doi:10.1056/NEJMcp032966
dc.sourceEM G, RA V. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother. 2002;49(6):999-1005.
dc.sourceRichard J-L, Sotto A, Jourdan N, et al. Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. DIABETES Metab. 35 2008;34(4):363-369. doi:10.1016/j.diabet.2008.02.005
dc.sourceWagner FW. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle. Foot Ankle Int. 1981;2:64-122. doi:10.1177/107110078100200202
dc.sourceMoura Neto A, Zantut-Wittmann DE, Parisi MCR, Fernandes TD, Nery M. Risk factors for ulceration and amputation in diabetic foot: Study in a cohort of 496 patients. Endocrine. 2013;44(1):119-124. doi:10.1007/s12020-012-9829- 2
dc.sourceStratton IM, Adler AI, Neil HAW, et al. Association Of Glycaemia With Macrovascular And Microvascular Complications Of Type 2 Diabetes (UKPDS 35): Prospective Observational Study. BMJ Br Med J. 2000;321(7258):405
dc.sourceAlmaramhy H, Mahabbat NA, Fallatah KY, Al-Ahmadi BA, Al-Alawi HH, Guraya SY. The correlation of fasting blood glucose levels with the severity of diabetic foot ulcers and the outcome of treatment strategies. Biomed Res. 2018;29(9):1961-1967.
dc.sourceSlater RA, Lazarovitch T, Boldur I, et al. Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med. 2004;21(7):705-709. doi:10.1111/j.1464-5491.2004.01221.
dc.sourceKandemir Ö, Akbay E, Şahin E, Milcan A, Gen R. Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms. J Infect. 2007;54(5):439-445. doi:10.1016/j.jinf.2006.08.013
dc.sourceGerding DN. Foot infections in diabetic patients: the role of anaerobes. Clin Infect Dis. 1995;20 Suppl 2:S283-8.
dc.sourceLipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): Prospective, randomised, controlled, double-blinded, multicentre trial. Lancet. 2005;366(9498):1695-1703. doi:10.1016/S0140- 6736(05)67694-5
dc.sourceCrouzet J, Lavigne JP, Richard JL, Sotto A. Diabetic foot infection: A critical review of recent randomized clinical trials on antibiotic therapy. Int J Infect Dis. 2011;15(9). doi:10.1016/j.ijid.2011.05.003
dc.sourceJones RN, Marshall WP. Does the Proximity of an Amputation, Length of Time Between Foot Ulcer Development and Amputation, or Glycemic Control at the Time of Amputation Affect the Mortality Rate of People with Diabetes who Undergo an Amputation? Adv Skin Wound Care. 2008;21(3):118-123. doi:10.1097/01.ASW.0000305419.73597.5f
dc.sourceHarkless L, Boghossian J, Pollak R, et al. An Open-Label, Randomized Study Comparing Efficacy and Safety of Intravenous Piperacillin/Tazobactam and Ampicillin/Sulbactam for Infected Diabetic Foot Ulcers. Surg Infect (Larchmt). 2005;6(1):27-40. doi:10.1089/sur.2005.6.27
dc.sourceLipsky BA, Holroyd KJ, Zasloff M. Topical versus Systemic Antimicrobial 36 Therapy for Treating Mildly Infected Diabetic Foot Ulcers: A Randomized, Controlled, Double‐Blinded, Multicenter Trial of Pexiganan Cream. Clin Infect Dis. 2008;47(12):1537-1545. doi:10.1086/593185
dc.sourceLipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet (London, England). 2005;366(9498):1695-1703. doi:10.1016/S0140-6736(05)67694-5
dc.sourceLipsky BA, Itani K, Norden C, Linezolid Diabetic Foot Infections Study Group. Treating Foot Infections in Diabetic Patients: A Randomized, Multicenter, Open‐Label Trial of Linezolid versus Ampicillin‐Sulbactam/Amoxicillin‐ Clavulanate. Clin Infect Dis. 2004;38(1):17-24. doi:10.1086/380449
dc.sourceFile TM. Highlights from 2012 infectious diseases society of America clinical practice guidelines for the diagnosis and treatment of diabetic foot infections. Infect Dis Clin Pract. 2013;21(1):43-45.
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectInfecciones en pie diabético
dc.subjectTratamiento en pie diabético
dc.subjectMicroorganismos en pie diabético
dc.subjectPie diabético
dc.subjectOsteomielitis
dc.titleInfecciones en pie diabético : gérmenes, tratamiento y desenlace en el Hospital Universitario Mayor - MEDERI
dc.typemasterThesis


Este ítem pertenece a la siguiente institución